Houston hospital named among smartest in the nation

hi, tech

The University of Texas MD Anderson Cancer Center was recognized for advancements in electronic functionality, AI and robotics. Photo via mdanderson.org

Houston hospitals are chock-full of smart people. But they’re also equipped with lots of “smart” technology. In fact, five local hospitals appear on Newsweek’s new list of the world’s best “smart” hospitals.

To compile the list, Newsweek teamed up with data provider Statista to rank the world’s top 330 hospitals for the use of smart technology. The ranking factors were electronic functionality, telemedicine, digital imaging, artificial intelligence (AI), and robotics.

The highest-ranked Houston hospital is the University of Texas MD Anderson Cancer Center, appearing at No. 6. The hospital was recognized for advancements in electronic functionality, AI and robotics.

“MD Anderson has a significant opportunity and a responsibility to our many stakeholders to create a digital ecosystem that promotes collaboration and advances scientific discovery to enhance patient outcomes,” David Jaffray, the cancer center’s chief technology and digital officer, said in a 2021 news release.

“Through our ongoing focus on enabling the use of new technologies to place quantitative data in context for our researchers,” Jaffray added, “we foster cutting-edge oncology data science to inform our cancer discovery research and to accelerate translation of our research findings into benefits for cancer patients.”

Ahead of MD Anderson on the list are:

  1. Mayo Clinic in Rochester, Minnesota.
  2. Cleveland Clinic in Cleveland.
  3. Massachusetts General Hospital in Boston.
  4. Johns Hopkins Hospital in Baltimore.
  5. Mount Sinai Hospital in New York City.

Other Houston hospitals on the list are:

  • Houston Methodist Hospital, No. 11.
  • Baylor St. Luke’s Medical Center, No. 105.
  • Texas Children’s Hospital, No. 197.
  • Memorial Hermann-Texas Medical Center, No. 266.
From Your Site Articles
CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

University of Houston-founded company secures $2.5M in NIH grant funding

all in the timing

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

Baylor College of Medicine's Jessica Watts, Dr. Jerome Pollet, and Dr. Paul Ling with Tess. Photo by Jackelin Reyna/Houston Zoo

Houston med school develops revolutionary mRNA vaccine for elephants

zoology biology

An innovative team from Baylor College of Medicine and Texas Children’s Hospital has worked with the Houston Zoo to develop a first-of-its-kind treatment for elephants, which has been administered to its first patient.

Tess, the beloved, 40-year-old matriarch of the Houston Zoo’s elephant herd, is recovering well after receiving the first-ever mRNA vaccine against elephant endotheliotropic herpesvirus (EEHV) 1A on Tuesday, June 18. The veterinary staff at the Houston Zoo will monitor Tess in the coming weeks to check her reaction and the efficacy of the vaccine.

EEHV 1A is a deadly infection for Asian Elephants. While generally benign in African Elephants, Asian Elephants can develop fatal hemorrhages. The fatality rate is a whopping 80 percent, making it one of the most serous threats to elephant populations outside of humans.

Anti-viral drugs have some effect on the disease, but two-thirds show no improvement. This has led to a search for a vaccine. For 15 years, the Houston Zoo and Dr. Paul Ling at Baylor College of Medicine’s Department of Virology and Microbiology have partnered to develop the drug. They have been helped by worldwide research from zoos and animal specialists, as well as graduate student Jessica Watts and Dr. Jeroen Pollet at Houston's Texas Children’s Hospital. The research has been funded by private donations, research partnerships, and grants.

Before being inoculated, the mRNA vaccine was exhaustively tested, with the dosage being extrapolated from data involving horses.

Houston Zoo veterinarians will periodically test Tess to see if she is developing the appropriate antibodies. If she is and there are no adverse reactions, the next step will be to administer the vaccine to the rest of the Houston herd. Many of these are Tess’s own children (Tucker, Tupelo, Tilly, and Teddy) and grandchildren (Winnie).

Should the vaccine prove effective, the doses will be made available worldwide to zoos and private elephant sanctuaries. It is likely to have a significant benefit on protecting and preserving the Asian Elephant population. As of January, there are fewer than 50,000 of the animas left in the wild. They are currently listed as endangered, and breeding programs and research done through the Houston Zoo are essential to keeping the animals from going extinct.

------

This article originally ran on CultureMap.

This uniquely Houston technology is an AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement. Photo via Getty Images

University of Houston lab reports breakthrough in cancer-detecting technology

making moves

T-cell immunotherapy is all the rage in the world of fighting cancer. A Houston company’s researchers have discovered a new subset of T cells that could be a game changer for patients.

CellChorus is a spinoff of Navin Varadarajan’s Single Cell Lab, part of the University of Houston’s Technology Bridge. The lab is the creator of TIMING, or Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visual AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement.

Last month, Nature Cancer published a paper co-authored by Varadarajan entitled, “Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.”

“Our results showed that a subset of T cells, labeled as CD8-fit T cells, are capable of high motility and serial killing, found uniquely in patients with clinical response,” says first author and recent UH graduate Ali Rezvan in Nature Cancer.

Besides him and Varadarajan, contributors hail from Baylor College of Medicine/Texas Children’s Hospital, MD Anderson Cancer Center, Kite Pharma, and CellChorus itself.

The team identified the CD80-fit T cells using TIMING to examine interactions between T cells and tumor cells across thousands of individual cells. They were able to integrate the results using single-cell RNA sequencing data.

T-cell therapy activates a patient’s own immune system to fight cancer cells, but not every patient responds favorably to it. Identifying CD8-fit cells could be the key to manufacturing clinical response even in those for whom immunotherapy hasn’t been effective.

“This work illustrates the excellence of graduate students Ali Rezvan and Melisa Montalvo; and post-doctoral researchers Melisa Martinez-Paniagua and Irfan Bandey among others,” says Varadarajan in a statement.

Earlier last month, CellChorus recently received a $2.5 million SBIR grant. The money allows the company to share TIMING more widely, facilitating even more landmark discoveries like CD8-fit cells.

A TMC-based organization supporting innovation pediatric medical devices has secured a $7.4 million grant. Photo via tmc.edu

Pediatric device consortium led by Baylor, Texas Children's lands $7.4M FDA grant

SWPDC scores

The Southwest National Pediatric Device Innovation Consortium announced this month that it has received a $7.4 million grant from the Food and Drug Administration to continue developing innovative pediatric medical devices.

Led by Baylor College of Medicine and Texas Children’s Hospital, SWPDC supports the development and commercialization of devices relating to children's health, including synthetic pediatric heart valves, miniature injection devices and neonatal intensive care unit monitoring devices, according to a statement from Baylor.

According to Dr. Chester Koh, SWPDC executive director and principal investigator, who is also a professor of urology at Baylor and a pediatric urologist at Texas Children’s, physicians today often have to treat pediatric patients with devices that are designed for larger adult bodies.

"This grant allows us to continue to spur development of devices specifically designed for kids by providing funding, consulting, clinical expertise and other assistance, all of which is made possible by our co-existence in the healthcare innovation ecosystem of the Texas Medical Center,” he said in the statement.

The SWPDC received a similar five-year grant in 2018 from the FDA, and has since added 200 pediatric device projects in all stages of development to its portfolio, raising in total more than $200 million in follow-on funding for the technology. It's one of five consortia in the FDA’s Pediatric Device Consortia (PDC), with others in Pennsylvania, Washington D.C., the San Francisco Bay Area, and Los Angeles.

Regionally, the consortium members include engineers from Texas A&M University, Rice University, University of Houston and the University of Minnesota, as it looks to expand into the midwest. It also partners with Texas Medical Center Innovation, JLABS@TMC and Proxima CRO.

In addition to the $7.4 million grant, SWPDC also received funding for its real-world data/real-world evidence (RWD/RWE) demonstration projects that focus on postoperative cardiac care, according to BCM.

Earlier this summer, Houston-based medtech company CorInnova was one of five companies invited to invited to present pitches at the National Capital Consortium for Pediatric Device Innovation’s “Make Your Medical Device Pitch for Kids!” competition. The event takes place this month and the companies are competing for a share of $150,000 in grant funding from the FDA. CorInnova has developed a minimally invasive device for the treatment of congestive heart failure.

Texas Children's Hospital and Baylor College of Medicine are working on a new COVID-19 vaccine candidate. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston health care organizations team up for the 'people's vaccine'

COVID Collaboration

Two major health care institutions in Houston — Texas Children's Hospital and the Baylor College of Medicine — are a step closer to rolling out what they dub the "people's vaccine" for COVID-19.

The two institutions, along with India-based vaccine and pharmaceutical company Biological E Ltd., have gained approval to move ahead this month with Phase III clinicals trials in India of a COVID-19 vaccine candidate called Corbevax. The Texas Children's Hospital Center for Vaccine Development developed the vaccine's protein antigen, which was licensed from the Baylor College of Medicine's BCM Ventures commercialization arm.

Unlike COVID-19 vaccines in the U.S., Corbevax contains the so-called "spike protein" from the surface of the novel coronavirus. Once that protein is injected via a vaccine, the body is supposed to begin building immunity against the protein and thereby prevent serious illness.

Experts envision Corbevax being a readily available weapon in the global fight against the COVID-19 pandemic, thanks to the simple vaccine platform (like the one used to prevent Hepatitis B) and the ability to store the vaccine in normal refrigerated settings. The targets of this vaccine are children and mothers.

"In the midst of India's public health crisis, it is our hope that our Texas Children's and Baylor COVID-19 vaccine can be released for emergency authorization in India and in all countries in need of essential COVID-19 vaccinations," Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development, says in a June 9 news release.

India has reported more than 29 million cases of COVID-19, causing 354,000 deaths. The country's COVID-19 surge reached its peak in May.

"The vaccines currently available cannot be manufactured quick enough to meet supply shortages in low-income countries," Hotez says. "Our vaccine is truly 'the people's vaccine,' created to serve the most marginalized and underserved populations that are hardest hit by this pandemic. This is the vaccine that could be used to vaccinate the world."

In the Phase III trial, the two-dose Corbevax vaccine will be administered to about 1,200 people age 18 to 80 at 15 sites in India. A larger global study of Corbevax is in the works.

According to India.com, Corbevax could be the most affordable COVID-19 vaccine available in the nation of nearly 1.37 billion people, costing close to $7 for a two-dose regimen. The Indian government already has preordered 300 million doses of Corbevax, which has shown promise in Phase I and Phase II trials. The Phase II trial ended in April.

If the Phase III trial goes as planned, doses could be widely administered as soon as August. Biological E initially plans to produce 75 million to 80 million doses per month, according to media reports. The Indian company foresees manufacturing at least 1 billion doses by the end of 2022.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston space tech co. rolls out futuristic lunar rover for NASA's Artemis missions

to the moon

Houston-based space exploration company Intuitive Machines just unveiled its version of a lunar terrain vehicle that’s designed to be used by astronauts in NASA’s Artemis moon discovery program.

Intuitive Machine recently rolled out its RACER lunar terrain vehicle (LTV) at Space Center Houston. RACER stands for Reusable Autonomous Crewed Exploration Rover.

The rover can accommodate two astronauts and nearly 900 pounds of cargo. In addition, it can pull a trailer loaded with almost 1,800 pounds of cargo.

Intuitive Machines will retain ownership and operational capabilities that will enable remote operation of the LTV between Artemis missions for about 10 years.

NASA chose Intuitive Machines and two other companies to develop advanced LTV capabilities.

“The objective is to enable Artemis astronauts, like the Apollo-era moonwalkers before them, to drive the rover, which features a rechargeable electric battery and a robotic arm, across the lunar surface, to conduct scientific research and prepare for human missions to Mars,” Intuitive Machines says in a post on its website.

The company tapped the expertise of Apollo-era moonwalkers Charlie Duke and Harrison Schmitt to design the pickup-truck-sized RACER. Intuitive Machines engineered the LTV in partnership with Atlas Devices, AVL, Barrios, Boeing, CSIRO, FUGRO, Michelin, Northrop Grumman, and Roush.

“This [project] strategically aligns with the Company’s flight-proven capability to deliver payloads to the surface of the Moon under [NASA’s] Commercial Lunar Payload Services initiative, further solidifying our position as a proven commercial contractor in lunar exploration,” says Steve Altemus, CEO of Intuitive Machines.

Astronauts at NASA’s Johnson Space Center are testing the static prototype of the company’s LTV. Meanwhile, the fully electric mobile demonstration LTV will undergo field testing later this month near Meteor Crater National Park in Arizona.

NASA expects to choose an LTV provider or providers in 2025.

- YouTubewww.youtube.com

Houston accelerator names inaugural cohort to propel digital transformation in energy

building tech

Houston-based Venture Builder VC has kicked off its NOV Supernova Accelerator and named its inaugural cohort.

The program, originally announced earlier this year, focuses on accelerating digital transformation solutions for NOV Inc.'s operations in the upstream oil and gas industry. It will support high-potential startups in driving digital transformation within the energy sector, specifically upstream oil and gas, and last five months and culminate in a demo day where founders will present solutions to industry leaders, potential investors, NOV executives, and other stakeholders.

The NOV Supernova Accelerator will work to cultivate relationships between startups and NOV. They will offer specific companies access to NOV’s corporate R&D teams and business units to test their solutions in an effort to potentially develop long-term partnerships.

“The Supernova Accelerator is a reflection of our commitment to fostering forward-thinking technologies that will drive the future of oil and gas,” Diana Grauer, director of R&D of NOV, says in a news release.

The cohort’s focus will be digital transformation challenges that combine with NOV’s vision and include data management and analytics, operational efficiency, HSE (Health, Safety, and Environmental) monitoring, predictive maintenance, and digital twins.

Startups selected for the program include:

  • AnyLog, an edge data management platform that replaces proprietary edge projects with a plug-and-play solution that services real-time data directly at the source, eliminating cloud costs, data transfer, and latency issues.
  • Equipt, an AI-powered self-serve platform that maximizes Asset & Field Service performance, and minimizes downtime and profit leakages.
  • Geolumina's platform is a solution that leverages data analytics to enhance skills, scale insights, and improve efficiency for subsurface companies.
  • Gophr acts as the "Priceline" of logistics, using AI to provide instant shipping quotes and optimize dispatch for anything from paper clips to rocket ships.
  • IoT++ simplifies industrial IoT with a secure, AI-enabled ecosystem of plug-and-play edge devices.
  • Kiana's hardware-agnostic solution secures people, assets, and locations using existing Wi-Fi, Bluetooth, UWB, and cameras, helping energy and manufacturing companies reduce risks and enhance operations.
  • Novity uses AI and physics models to accurately predict machine faults, helping factory operators minimize downtime by knowing the remaining useful life of their machines.
  • Promecav is redefining crude oil conditioning with patented technology that slashes water use and energy while reducing toxic exposure for safer, cleaner, and more sustainable oil processing.
  • RaftMind's enterprise AI solution transforms how businesses manage knowledge. Our advanced platform makes it easier to process data and unlock insights from diverse sources.
  • Spindletop AI uses edge-based machine learning to make each well an autonomous, self-optimizing unit, cutting costs, emissions, and cloud dependence.
  • Taikun.aicombines generative AI with SCADA data to create virtual industrial engineers, augmenting human teams for pennies an hour.
  • Telemetry Insight’s platform utilizes high-resolution accelerometer data to simplify oilfield monitoring and optimize marginal wells for U.S. oil and gas producers via actionable insights.
  • Visual Logging utilizes fiber optic and computer vision technology to deliver real-time monitoring solutions, significantly enhancing data accuracy by providing precise insights into well casing integrity and flow conditions.

“Each startup brings unique solutions to the table, and we are eager to see how these technologies will evolve with NOV’s support and expertise,” Billy Grandy, general partner of Venture Builder VC, says in the release. “This partnership reflects our ongoing commitment to nurturing talent and driving innovation within the energy sector.”

Venture Builder VC is a consulting firm, investor, and accelerator program.

“Unlike mergers and acquisitions, the venture client model allows corporations like NOV to quickly test and implement new technologies without committing to an acquisition or risking significant investment,” Grandy previously said about the accelerator program.

------

This article originally ran on EnergyCapital.

Rice, UH keep top spots on annual ranking, startup closes $5.6M, and more trending Houston innovation news

top stories

Editor's note:Let's roundup the most-read Houston innovation news from the week. Trending Houston tech and startup articles from InnovationMap and its daily newsletter included profiles on Houston Innovation Awards honorees, Rice University and the University of Houston continuing their reigns on an annual ranking, and more.

Houston schools lead rankings for best entrepreneurship programs for 6th consecutive year

Rice University and the University of Houston have maintained their top spots for entrepreneurship studies across graduate and undergraduate rankings, respectively. Photo via Getty Images

Rice University and the University of Houston have once again topped The Princeton Review and Entrepreneur’s lists of the best graduate and undergraduate schools for entrepreneurship studies.

Rice ranks first in the graduate category for the sixth consecutive year, and UH ranks first in the undergraduate category for the sixth consecutive year.

“At Rice Business, our students learn both inside and outside the classroom, drawing on our strong industry and community connections in Houston and beyond,” says Peter Rodriguez, dean of Rice’s Jones Graduate School of Business. “With small class sizes and tailored programs, we aim to equip our students with the skills to create new ventures and excel in a fast-changing business landscape.” Continue reading.

Meet 5 of the fastest-growing scaleup companies in Houston

These five scaleups stood out to the judges of the 2024 Houston Innovation Awards. Photo via Getty Images

The 2024 Houston Innovation Awards will feature a new category: Scaleup of the Year, which honors a Bayou City company that's seen impressive growth in 2024.

From biotech companies to decarbonization startups, the inaugural finalists have expanded internationally, moved to larger facilities, completed clinical trials and more. Read on to learn more about these fast-growing startups. Continue reading.

Houston-based, NASA-founded tech startup closes $5.6M in seed funding

Helix Earth's technology is estimated to save up to half of the net energy used in commercial air conditioning, reducing both emissions and costs for operators. Photo via Getty Images

A Houston startup with clean tech originating out of NASA has secured millions in funding.

Helix Earth Technologies closed an oversubscribed $5.6 million seed funding led by Houston-based research and investment firm Veriten. Anthropocene Ventures, Semilla Capital, and others including individual investors also participated in the round.

“This investment will empower the Helix Earth team to accelerate the development and deployment of our first groundbreaking hardware technology designed to disrupt a significant portion of the commercial air conditioning market, an industry that is ready for innovation,” Rawand Rasheed, Helix Earth co-founder and CEO, says in a news release. Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

These are 6 of the organizations best supporting Houston's innovation community

Get to know the Houston Innovation Awards Community Champion Organization finalists. Photo via Getty Images

It takes a village to launch, run, and grow an innovative startup.

And from helping founders gain access to capital to promoting diversity, offering mentorship and hosting pitch events, demo days and more, this year's six Community Champion Organization finalists are part of that village. Learn about each of the finalists and what drives them to support the Houston innovation ecosystem in the interviews below. Continue reading.

View All Listings